Buy Johnson & Johnson

Logo for stock JNJ (Johnson & Johnson)

Amount

£
GBP

Latest price

$176.48
(£1.00 = $1.348)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$429.672B

P/E ratio

19.09

EPS

$9.344

Beta

0.39

Dividend rate

$5.02

Dividend yield

2.81%

About

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.

CEO

Mr. Joaquin Boix Duato

Employees

138,100

Sector

Health

Company HQ

NEW BRUNSWICK, United States of America

Website

News

Logo for news article #0 (2 High-Conviction Picks For 7.73% Growth And 4.22% Yield Within A Dividend Portfolio)

2 High-Conviction Picks For 7.73% Growth And 4.22% Yield Within A Dividend Portfolio

Through our latest additions of Deutsche Post and Meta Platforms to The Dividend Income Accelerator Portfolio, we have increased the portfolio's sector diversification and global exposure. In addition to that, we have increased the portfolio's potential for dividend growth and capital appreciation. Our portfolio balances income and dividend growth, reflected in the portfolio's Weighted Average Yield on Cost [TTM] of 4.22% and 5-Year Weighted Average Dividend Growth Rate [CAGR] of 7.73%.

Seeking Alpha

August 26, 2025

Logo for news article #1 (J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?)

J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?

Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.

Zacks Investment Research

August 25, 2025

Logo for news article #2 (5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones)

5 Blue-Chip Stocks to Buy as the Dow Achieves New Milestones

JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.

Zacks Investment Research

August 25, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.